DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

956 FitzGerald GA. Mechanisms of platelet activation:
Thromboxane A2 as an amplifying signal for other agonists.
Am J Cardiol, 1991, 68:11B–15B.
FitzGerald GA, Loll P. COX in a crystal ball: Current status and
future promise of prostaglandin research. J Clin Invest, 2001,
107:1335–1337.
Furstenberger G, Epp N, Eckl KM, et al. Role of epidermis-type
lipoxygenases for skin barrier function and adipocyte differentiation.
Prostaglandins Other Lipid Mediat, 2007, 82:128–134.
Grosser T, Fries S, Fitzgerald GA. Biological basis for the cardiovascular
consequences of COX-2 inhibition: Therapeutic
challenges and opportunities. J Clin Invest, 2006, 116:4–15.
Hao CM, Breyer MD. Physiologic and pathophysiologic roles of
lipid mediators in the kidney. Kidney Int, 2007, 71:1105–1115.
Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen,
and other non-steroidal anti-inflammatory drugs in cancer
prevention: A critical review of non-selective COX-2 blockade
(review). Oncol Rep, 2005, 13:559–583.
Hirata T, Kakizuka A, Ushikubi F, et al. Arg60 to Leu mutation
of the human thromboxane A2 receptor in a dominantly inherited
bleeding disorder. J Clin Invest, 1994, 94:1662–1667.
Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor.
J Biochem, 2002, 131:773–779.
Imig JD, Zhao X, Falck JR, et al. Enhanced renal microvascular
reactivity to angiotensin II in hypertension is ameliorated by
the sulfonimide analog of 11,12-epoxyeicosatrienoic acid.
J Hypertens, 2001, 19:983–992.
Ishii S, Nagase T, Shimizu T. Platelet-activating factor receptor.
Prostaglandins Other Lipid Mediat, 2002, 68–69:599–609.
Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and
genetically engineered PAF receptor mutant mice. Prog Lipid
Res, 2000, 39:41–82.
Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors:
Cellular distribution and function in immune and inflammatory
responses. J Immunol, 2004, 173:1503–1510.
Kim N, Luster AD. Regulation of immune cells by eicosanoid
receptors. ScientificWorldJournal, 2007, 7:1307–1328.
King VL, Trivedi DB, Gitlin JM, et al. Selective cyclooxygenase-2
inhibition with celecoxib decreases angiotensin II-induced
abdominal aortic aneurysm formation in mice. Arterioscler
Thromb Vasc Biol, 2006, 26:1137–1143.
Kroetz DL, Xu F. Regulation and inhibition of arachidonic acid
omega-hydroxylases and 20-HETE formation. Annu Rev
Pharmacol Toxicol, 2005, 45:413–438.
Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary
hemodynamics during intravenous epoprostenol
(prostacyclin): A study of 15 patients with moderate to severe
portopulmonary hypertension. Hepatology, 1999, 30:641–648.
Kulkarni SK, Singh VP. Licofelone—A novel analgesic and antiinflammatory
agent. Curr Top Med Chem, 2007, 7:251–263.
Kunapuli P, Lawson JA, Rokach J, et al. Functional characterization
of the ocular prostaglandin f2alpha (PGF2alpha) receptor.
Activation by the isoprostane, 12-iso-PGF2alpha. J Biol
Chem, 1997, 272:27147–27154.
Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: Formation,
analysis and use as indices of lipid peroxidation in vivo. J Biol
Chem, 1999, 274:24441–24444.
LeLeiko RM, Vaccari CS, Sola S, et al. Usefulness of elevations
in serum choline and free F(2)-isoprostane to predict 30-day
cardiovascular outcomes in patients with acute coronary syndrome.
Am J Cardiol, 2009, 104:638–643.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2
is sufficient to induce tumorigenesis in transgenic
mice. J Biol Chem, 2001, 276:18563–18569.
Lopez-Novoa JM. Potential role of platelet activating factor in
acute renal failure. Kidney Int, 1999, 55:1672–1682.
Matsuoka T, Narumiya S. Prostaglandin receptor signaling in
disease. ScientificWorldJournal, 2007, 7:1329–1347.
McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic
biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The
human pharmacology of a selective inhibitor of COX-2. Proc
Natl Acad Sci U S A, 1999, 96:272–277.
McIntyre TM, Prescott SM, Stafforini DM. The emerging roles
of PAF acetylhydrolase. J Lipid Res, 2009, 50(suppl):
S255–S259.
McMahon B, Godson C. Lipoxins: Endogenous regulators of inflammation.
Am J Physiol Renal Physiol, 2004, 286:F189–F201.
Milne GL, Yin H, Morrow JD. Human biochemistry of the isoprostane
pathway. J Biol Chem, 2008, 283:15533–15537.
Narumiya S, FitzGerald GA. Genetic and pharmacological
analysis of prostanoid receptor function. J Clin Invest, 2001,
108:25–30.
Ninio E, Tregouet D, Carrier JL, et al. Platelet-activating factoracetylhydrolase
and PAF-receptor gene haplotypes in relation
to future cardiovascular event in patients with coronary artery
disease. Hum Mol Genet, 2004, 13:1341–1351.
Nüsing RM, Reinalter SC, Peters M, et al. Pathogenetic role of
cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal
Bartter syndrome: Therapeutic use of the cyclooxygenase-2
inhibitor nimesulide. Clin Pharmacol Ther, 2001, 70:384–390.
O’Shaughnessy KM, Karet FE. Salt handling and hypertension.
J Clin Invest, 2004, 113:1075–1081.
Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J
Med, 2007, 357:1841–1854.
Pettipher R, Hansel TT, Armer R. Antagonism of the
prostaglandin D2 receptors DP1 and CRTH2 as an approach to
treat allergic diseases. Nat Rev Drug Discov, 2007, 6:313–325.
Prescott SM, McIntyre TM, Zimmerman GA, et al. Sol Sherry
lecture in thrombosis: Molecular events in acute inflammation.
Arterioscler Thromb Vasc Biol, 2002, 22:727–733.
Prescott SM, Zimmerman GA, Stafforini DM, et al. Plateletactivating
factor and related lipid mediators. Annu Rev
Biochem, 2000, 69:419–445.
Qian JY, Harding P, Liu Y, et al. Reduced cardiac remodeling
and function in cardiac-specific EP4 receptor knockout mice
with myocardial infarction. Hypertension, 2008, 51:
560–566.
Rocca B, Secchiero P, Ciabattoni G, et al. Cyclooxygenase-2
expression is induced during human megakaryopoiesis and
characterizes newly formed platelets. Proc Natl Acad Sci U S A,
2002, 99:7634–7639.
Salomon RG, Subbanagounder G, O’Neil J, et al. Levuglandin
E2-protein adducts in human plasma and vasculature. Chem
Res Toxicol, 1997, 10:536–545.
Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane
prostaglandin E synthase-1: A novel therapeutic target.
Pharmacol Rev, 2007, 59:207–224.
Schuster VL. Prostaglandin transport. Prostaglandins Other
Lipid Mediat, 2002, 68–69:633–647.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation:
Dual anti-inflammatory and pro-resolution lipid mediators.
Nat Rev Immunol, 2008, 8:349–361.